search
Back to results

Effect of Medical Food on Reducing Asthma Symptoms in Asthmatic Children

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
medical food with EPA and GLA, vitamins and minerals
medical food minus EPA and GLA, antioxidant vitamins/minerals
Sponsored by
Abbott Nutrition
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

6 Years - 14 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female children who have had mild to moderate persistent asthma for at least 1 year and are between 6 and 14 years of age, and not currently being treated with steroids are eligible.

Each subject also has to have:

  • Subject is off of controller therapy 4 wks preceding visit 1.
  • Mild to moderate persistent asthma
  • Methacholine responsiveness with an FEV1 PC20
  • Able to perform reproducible spirometry
  • Verbal assent in addition to consent
  • History of prior clinical varicella or varicella vaccine.
  • Nonsmoker in past year.

Exclusion Criteria:

  • Asthma symptoms and/or albuterol use consistent with severe persistent asthma during the run-in period.
  • Subject with FEV1 < 80% predicted at visit 1 or FEV1 < 70% predicted at visit 2.
  • Two or more hospitalizations for asthma in the past year.
  • Subject has received oral, nasal, inhaled, or IM corticosteroids during the preceding month.
  • Subject has received leukotriene modifiers, theophylline derivatives, or mast cell stabilizers for asthma within 4 weeks before visit 1
  • Subject is receiving one or more of the following medications:

    • Astemizole prior to 3 months of visit 1
    • Oral, inhaled or parenteral corticosteroids prior to 4 weeks of visit 1
    • Cromolyn, antimuscarinics, cimetidine, metoclopramide, phenobarbital, phenytion, terfenadine, loratadine, or anticholingeric agents prior to 2 weeks of visit 1.
    • Theophylline prior to 4 weeks of visit 1
  • Subject with active upper respiratory tract infection prior to 4 weeks before visit 1
  • Subject with acute sinus disease requiring antibiotic treatment within 1 week before visit
  • Subject with an emergency department treatment for asthma within 1 month, prior intubation for asthma, or hospitalization for asthma within 3 months
  • Subject has known bleeding disorder and/or is on medication known to have significant anticoagulant effects.
  • Subject has known hypersensitivity to any of the ingredients
  • Subject is taking either pill, powder, or liquid forms of nutritional and/or health food supplements within the past 4 weeks prior to visit
  • Subject unable to tolerate or unwilling to take the full dose of the nutritional study formulas
  • Cystic fibrosis or any other chronic lung disease other than asthma.
  • Subject having gastroesophogeal reflux undergoing medical treatment
  • Significant medical illness other than asthma that could require oral corticosteroids during the study.
  • Subject is receiving allergen hyposensitization therapy other than an established maintenance regimen
  • Subject has received IV globulins or immunosuppressants.
  • Subject is known to be human immunodeficiency virus (HIV) positive.
  • Pregnancy or lactation.
  • If of child bearing potential, failure to practice abstinence or use of an acceptable birth control method.
  • Subject is morbidly obese

Sites / Locations

  • National Jewish Health

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

novel nutritional formula

Control nutritional product

Arm Description

1 8oz serving per day for 12 weeks

Outcomes

Primary Outcome Measures

asthma free days

Secondary Outcome Measures

reduction of airway hyper-responsiveness
time to the first asthma exacerbation
respiratory function (spirometry)
need for rescue for exacerbations of asthma symptoms.

Full Information

First Posted
March 8, 2010
Last Updated
March 15, 2010
Sponsor
Abbott Nutrition
search

1. Study Identification

Unique Protocol Identification Number
NCT01087710
Brief Title
Effect of Medical Food on Reducing Asthma Symptoms in Asthmatic Children
Official Title
Effect of Novel Medical Food on Reducing the Frequency and Severity of Asthma Symptoms and Airway Hyper-responsiveness in Children With Mild to Moderate Persistent Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
March 2010
Overall Recruitment Status
Completed
Study Start Date
July 2004 (undefined)
Primary Completion Date
December 2005 (Actual)
Study Completion Date
January 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Abbott Nutrition

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To determine the effect of medical food on reducing asthma symptoms in asthmatic children.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
43 (Actual)

8. Arms, Groups, and Interventions

Arm Title
novel nutritional formula
Arm Type
Experimental
Arm Title
Control nutritional product
Arm Type
Active Comparator
Arm Description
1 8oz serving per day for 12 weeks
Intervention Type
Other
Intervention Name(s)
medical food with EPA and GLA, vitamins and minerals
Intervention Description
1 8oz serving per day for 12 weeks
Intervention Type
Other
Intervention Name(s)
medical food minus EPA and GLA, antioxidant vitamins/minerals
Intervention Description
1 8oz serving a day for 12 weeks
Primary Outcome Measure Information:
Title
asthma free days
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
reduction of airway hyper-responsiveness
Time Frame
12 weeks
Title
time to the first asthma exacerbation
Time Frame
12 weeks
Title
respiratory function (spirometry)
Time Frame
12 weeks
Title
need for rescue for exacerbations of asthma symptoms.
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female children who have had mild to moderate persistent asthma for at least 1 year and are between 6 and 14 years of age, and not currently being treated with steroids are eligible. Each subject also has to have: Subject is off of controller therapy 4 wks preceding visit 1. Mild to moderate persistent asthma Methacholine responsiveness with an FEV1 PC20 Able to perform reproducible spirometry Verbal assent in addition to consent History of prior clinical varicella or varicella vaccine. Nonsmoker in past year. Exclusion Criteria: Asthma symptoms and/or albuterol use consistent with severe persistent asthma during the run-in period. Subject with FEV1 < 80% predicted at visit 1 or FEV1 < 70% predicted at visit 2. Two or more hospitalizations for asthma in the past year. Subject has received oral, nasal, inhaled, or IM corticosteroids during the preceding month. Subject has received leukotriene modifiers, theophylline derivatives, or mast cell stabilizers for asthma within 4 weeks before visit 1 Subject is receiving one or more of the following medications: Astemizole prior to 3 months of visit 1 Oral, inhaled or parenteral corticosteroids prior to 4 weeks of visit 1 Cromolyn, antimuscarinics, cimetidine, metoclopramide, phenobarbital, phenytion, terfenadine, loratadine, or anticholingeric agents prior to 2 weeks of visit 1. Theophylline prior to 4 weeks of visit 1 Subject with active upper respiratory tract infection prior to 4 weeks before visit 1 Subject with acute sinus disease requiring antibiotic treatment within 1 week before visit Subject with an emergency department treatment for asthma within 1 month, prior intubation for asthma, or hospitalization for asthma within 3 months Subject has known bleeding disorder and/or is on medication known to have significant anticoagulant effects. Subject has known hypersensitivity to any of the ingredients Subject is taking either pill, powder, or liquid forms of nutritional and/or health food supplements within the past 4 weeks prior to visit Subject unable to tolerate or unwilling to take the full dose of the nutritional study formulas Cystic fibrosis or any other chronic lung disease other than asthma. Subject having gastroesophogeal reflux undergoing medical treatment Significant medical illness other than asthma that could require oral corticosteroids during the study. Subject is receiving allergen hyposensitization therapy other than an established maintenance regimen Subject has received IV globulins or immunosuppressants. Subject is known to be human immunodeficiency virus (HIV) positive. Pregnancy or lactation. If of child bearing potential, failure to practice abstinence or use of an acceptable birth control method. Subject is morbidly obese
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stehen DeMichele, PhD
Organizational Affiliation
Abbott Nutrition
Official's Role
Study Chair
Facility Information:
Facility Name
National Jewish Health
City
Denver
State/Province
Colorado
ZIP/Postal Code
80206
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
20545703
Citation
Covar R, Gleason M, Macomber B, Stewart L, Szefler P, Engelhardt K, Murphy J, Liu A, Wood S, DeMichele S, Gelfand EW, Szefler SJ. Impact of a novel nutritional formula on asthma control and biomarkers of allergic airway inflammation in children. Clin Exp Allergy. 2010 Aug;40(8):1163-74. doi: 10.1111/j.1365-2222.2010.03523.x. Epub 2010 Jun 7.
Results Reference
derived

Learn more about this trial

Effect of Medical Food on Reducing Asthma Symptoms in Asthmatic Children

We'll reach out to this number within 24 hrs